Evidence map›Paper›PMID 32998441›Full record

ArticleCancers2020

Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation.

Aleksandar Radujkovic, Lambros Kordelas, Rashit Bogdanov, Carsten Müller-Tidow, Dietrich W Beelen, Peter Dreger, Thomas Luft

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Aleksandar RadujkovicDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-8543-5016
Lambros KordelasDepartment of Bone Marrow Transplantation, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0003-3116-473X
Rashit BogdanovDepartment of Bone Marrow Transplantation, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Carsten Müller-TidowDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Dietrich W BeelenDepartment of Bone Marrow Transplantation, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Peter DregerDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Thomas LuftDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Heidelberg University · DEUniversity of Duisburg-Essen · DE

Funding

B.L.U.T. e.V. (Weingarten, Germany) naHelmholtz-Alliance on Immunotherapy of Cancer naWilhelm-Sander-Stiftung GrantNo. 2008.068.1
6 · The paper itself

Abstract

Interleukin-18 (IL-18) is an immunoregulatory cytokine and a context-dependent regulator of hematopoietic stem/progenitor cell (HSPC) quiescence in murine models. In a previous study, high pre-conditioning levels of IL-18 were associated with increased non-relapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). To investigate the clinical impact of IL-18 status on hematopoietic function, the associations of pre-conditioning and day 0-3 cytokine levels with platelet and neutrophil recovery were analyzed in a training cohort of 714 allografted patients. In adjusted logistic regression analyses, both increasing pre-conditioning and day 0-3 IL-18 levels had a significantly higher adjusted odds ratio (aOR) of delayed platelet and neutrophil recovery on day +28 post-transplant (aOR per two-fold increase: 1.6-2.0). The adverse impact of high pre-conditioning IL-18 on day +28 platelet recovery was verified in an independent cohort of 673 allografted patients (aOR per two-fold increase: 1.8 and 1.7 for total and free IL-18, respectively). In both cohorts, a platelet count ≤20/nL on day +28 was associated with a significantly increased hazard of NRM (hazard ratio 2.13 and 2.94, respectively). Our findings support the hypothesis that elevated peritransplant IL-18 levels affect post-transplant HSPC function and may provide a rationale to explore modulation of IL-18 for improving alloSCT outcomes.

Indexed as

allogeneic stem cell transplantationhematopoietic recoveryinterleukin-18non-relapse mortality

Identifiers

PMID32998441
PMCPMC7601738
OpenAlexW3088796231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.